ada glp 1 recommendations

ada glp 1 recommendations GLP-1 Use Increased Significantly Among Pediatric Patients With T2D in Past 5 Years | 2025 ADA 2015 Guidelines, Part 3

Name: ada glp 1 recommendations GLP-1 Use Increased Significantly Among Pediatric Patients With T2D in Past 5 Years | 2025 ADA 2015 Guidelines, Part 3
Brand: 2m-capital.com
SKU: 63309359765
Price: 22.09 USD
Availability: InStock
Rating: 4.3411 (17 reviews)

SKU: 63309359765

4.3

EUR22.09 EUR45.09

Pay in 4 interest-free payments of $5.52 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Nov 9 - Nov 14

Description

JAMA Intern Med 185, 778 (2025)

A double-blind placebo-controlled study of exenatide for the treatment of weight gain associated with olanzapine in overweight or obese adults with bipolar disorder, major depressive disorder, schizophrenia or schizoaffective disorder

GLP-1 RAs, also known as GLP-1 analogs or incretin mimetics, simulate GLP-1 effects, and, as such, were originally utilized for the treatment of T2D and obesity (improving glucose homeostasis and modulating the sense of appetite, with low risk of hypoglycemia)